Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors

Summary

This study is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of IBR854 cell injection in patients with unresectable, locally advanced, or metastatic solid tumors.

Timeline

Start

2023-09-01

Primary completion

2024-12-26

Completion

2024-12-26

Publications

• Sun L, Ma P, Miao Z, Su N, Bian J, Wang S, Li N. Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial. Cancer Immunol Immunother. 2026 Jul 6. doi: 10.1007/s00262-026-04481-1. Online ahead of print.

Drugs

Indications